Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses

Travis W. Lim, Ji Yuan, Zhen Liu, Dexin Qiu, Alhousseynou Sall, Decheng Yang

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Positive single-stranded RNA viruses constitute a broad and prevalent group of pathogens that threaten human health and life worldwide. While effective vaccines have been developed for some, such as poliovirus and hepatitis A, others such as coxsackievirus, severe acute respiratory syndrome coronavirus (SARS-CoV) and West Nile virus have no accredited drug treatments. Antisense technologies, which encompass small interfering RNA, antisense oligonucleotides, ribozymes and their chemically modified analogs, involve small sequence-specific nucleic-acid-based molecules that inhibit viral replication at the level of translation. Many antisense oligomers are proven antiviral agents in vitro. In this review, we provide an overview of the antiviral antisense field, highlighting specific studies of interest over the past several years, using our experience with coxsackievirus B3 as a reference point. Overall, both the challenges and successes of existing antisense therapies for positive single-stranded RNA viruses can be paralleled to those for other virus groups, and vice versa.

Original languageEnglish (US)
Pages (from-to)104-107
Number of pages4
JournalCurrent Opinion in Molecular Therapeutics
Volume8
Issue number2
StatePublished - Apr 1 2006

Fingerprint

Enterovirus
RNA Viruses
Nucleic Acids
Antiviral Agents
Severe Acute Respiratory Syndrome
West Nile virus
Catalytic RNA
Coronavirus
Poliovirus
Hepatitis A
Antisense Oligonucleotides
Small Interfering RNA
Vaccines
Viruses
Technology
Pharmaceutical Preparations
Therapeutics
In Vitro Techniques
Global Health

Keywords

  • Antisense
  • Antiviral drug therapy
  • Coxsackievirus
  • Phosphorodiamidate morpholino oligomers (PMO)
  • Positive single-stranded RNA virus (+ssRNA virus)
  • Small interfering RNA (siRNA)

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this

Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses. / Lim, Travis W.; Yuan, Ji; Liu, Zhen; Qiu, Dexin; Sall, Alhousseynou; Yang, Decheng.

In: Current Opinion in Molecular Therapeutics, Vol. 8, No. 2, 01.04.2006, p. 104-107.

Research output: Contribution to journalReview article

Lim, Travis W. ; Yuan, Ji ; Liu, Zhen ; Qiu, Dexin ; Sall, Alhousseynou ; Yang, Decheng. / Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses. In: Current Opinion in Molecular Therapeutics. 2006 ; Vol. 8, No. 2. pp. 104-107.
@article{c9267fd459c64ca78e40a3af0b3b7b22,
title = "Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses",
abstract = "Positive single-stranded RNA viruses constitute a broad and prevalent group of pathogens that threaten human health and life worldwide. While effective vaccines have been developed for some, such as poliovirus and hepatitis A, others such as coxsackievirus, severe acute respiratory syndrome coronavirus (SARS-CoV) and West Nile virus have no accredited drug treatments. Antisense technologies, which encompass small interfering RNA, antisense oligonucleotides, ribozymes and their chemically modified analogs, involve small sequence-specific nucleic-acid-based molecules that inhibit viral replication at the level of translation. Many antisense oligomers are proven antiviral agents in vitro. In this review, we provide an overview of the antiviral antisense field, highlighting specific studies of interest over the past several years, using our experience with coxsackievirus B3 as a reference point. Overall, both the challenges and successes of existing antisense therapies for positive single-stranded RNA viruses can be paralleled to those for other virus groups, and vice versa.",
keywords = "Antisense, Antiviral drug therapy, Coxsackievirus, Phosphorodiamidate morpholino oligomers (PMO), Positive single-stranded RNA virus (+ssRNA virus), Small interfering RNA (siRNA)",
author = "Lim, {Travis W.} and Ji Yuan and Zhen Liu and Dexin Qiu and Alhousseynou Sall and Decheng Yang",
year = "2006",
month = "4",
day = "1",
language = "English (US)",
volume = "8",
pages = "104--107",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "2",

}

TY - JOUR

T1 - Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses

AU - Lim, Travis W.

AU - Yuan, Ji

AU - Liu, Zhen

AU - Qiu, Dexin

AU - Sall, Alhousseynou

AU - Yang, Decheng

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Positive single-stranded RNA viruses constitute a broad and prevalent group of pathogens that threaten human health and life worldwide. While effective vaccines have been developed for some, such as poliovirus and hepatitis A, others such as coxsackievirus, severe acute respiratory syndrome coronavirus (SARS-CoV) and West Nile virus have no accredited drug treatments. Antisense technologies, which encompass small interfering RNA, antisense oligonucleotides, ribozymes and their chemically modified analogs, involve small sequence-specific nucleic-acid-based molecules that inhibit viral replication at the level of translation. Many antisense oligomers are proven antiviral agents in vitro. In this review, we provide an overview of the antiviral antisense field, highlighting specific studies of interest over the past several years, using our experience with coxsackievirus B3 as a reference point. Overall, both the challenges and successes of existing antisense therapies for positive single-stranded RNA viruses can be paralleled to those for other virus groups, and vice versa.

AB - Positive single-stranded RNA viruses constitute a broad and prevalent group of pathogens that threaten human health and life worldwide. While effective vaccines have been developed for some, such as poliovirus and hepatitis A, others such as coxsackievirus, severe acute respiratory syndrome coronavirus (SARS-CoV) and West Nile virus have no accredited drug treatments. Antisense technologies, which encompass small interfering RNA, antisense oligonucleotides, ribozymes and their chemically modified analogs, involve small sequence-specific nucleic-acid-based molecules that inhibit viral replication at the level of translation. Many antisense oligomers are proven antiviral agents in vitro. In this review, we provide an overview of the antiviral antisense field, highlighting specific studies of interest over the past several years, using our experience with coxsackievirus B3 as a reference point. Overall, both the challenges and successes of existing antisense therapies for positive single-stranded RNA viruses can be paralleled to those for other virus groups, and vice versa.

KW - Antisense

KW - Antiviral drug therapy

KW - Coxsackievirus

KW - Phosphorodiamidate morpholino oligomers (PMO)

KW - Positive single-stranded RNA virus (+ssRNA virus)

KW - Small interfering RNA (siRNA)

UR - http://www.scopus.com/inward/record.url?scp=33645702636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645702636&partnerID=8YFLogxK

M3 - Review article

C2 - 16610761

AN - SCOPUS:33645702636

VL - 8

SP - 104

EP - 107

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 2

ER -